Vital Therapies, Inc. Receives Orphan Designation in Europe

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Vital Therapies, Inc. Receives Orphan Designation in Europe

SAN DIEGO, CA--(Marketwired - Aug 5, 2013) -  Vital Therapies®, Inc., a biopharmaceutical company focused on developing a cell-based therapy targeting the treatment of acute liver failure, today announced that the European Commission granted Orphan Medicinal Product Designation for C3A cells for the treatment of acute liver failure. These cells, which the company grows from its proprietary cell bank, serve as the active ingredient in ELAD®, the company's investigational artificial liver therapy. 

Under EMA guidelines, Orphan Designation provides 10 years of potential market exclusivity if the designated product candidate is approved for marketing in the European Union and the designation is maintained. Orphan status also permits EMA assistance in optimizing the candidate's clinical development through participation in designing clinical protocols and preparing the marketing application. Finally, a drug candidate designated by the EMA as an Orphan Medicinal Product qualifies for a reduction in fees associated with the filing of a market authorization application and other regulatory fees associated with obtaining regulatory approval.

Vital Therapies has already received Orphan Designation in the United States for C3A cells in the treatment of acute liver failure. As such, if the company receives marketing approval for ELAD in this indication, the FDA could not approve another therapy whose active ingredient includes C3A cells for the treatment of acute liver failure, except in very limited circumstances, for up to seven years.

In other news, Vital Therapies, Inc. completed the closing of a financing tranche earlier this summer. This financing represents the third scheduled tranche of a broader financing initially announced in September of 2012. The total amount raised under this financing exceeds $60 million, of which $31 million was raised in June of 2013. 

About Vital Therapies, Inc.

Vital Therapies, Inc. is a biopharmaceutical company based in San Diego, California. The company is developing ELAD, an investigational extracorporeal bio-artificial liver therapy which has been studied in six clinical trials in US, EU and Asia. The company currently has the first of three planned phase 3 clinical trials underway, with the remaining two clinical trials anticipated to begin enrolling subjects later in 2013.

About ELAD

ELAD is an allogeneic cellular therapy system based on our human liver-derived cells combined with a reusable bedside unit. We have customized the now-publicly available C3A cell line to create an optimized bank of cells for use in ELAD which we culture and expand through proprietary techniques. These cells have been shown to retain many key synthetic and metabolic processes of normal human hepatocytes, the primary functional cell of the liver. During ELAD therapy, blood plasma is drawn from the patient via our reusable bedside unit into the ELAD cartridges, which collectively contain 440 grams, or approximately one pound of C3A cells. The patient's blood plasma is treated by our C3A cells in a single session of continuous therapy lasting between three and ten days. We believe that ELAD therapy facilitates the recovery of liver function and has the potential to increase survival.

Vital Therapies® and ELAD® are trademarks of Vital Therapies, Inc.

This press release may contain forward-looking statements, including but not limited to, statements regarding our phase 3 clinical trials, anticipated potential benefits of the ELAD system, and expected advantages of orphan drug designations in Europe and the United States. These statements relate to future events and are subject to risks, uncertainties and assumptions about Vital Therapies, Inc., including the risks that our clinical trials may not be successful and that we may fail to receive marketing approval for ELAD in the jurisdiction. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement. We do not undertake to update any forward-looking statements.

CONTACT: Terry Winters Co-Chairman & Chief Executive Officer Duane Nash Chief Business Officer Vital Therapies, Inc. 858-673-6840

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Why Dent Repair Estimates Need More Than a Simple Ruler

Updated Category News Views 118

A dent can look harmless in a parking-lot glare and still turn into a stubborn repair job once somebody examines the metal properly. That is the useful, unglamorous point Jason Phelps of Magic Dent makes in a HelloNation article: visible diameter is not a verdict. Anybody shopping for vehicle repairs, managing fleet costs, or watching the collision-service ecosystem ought...

Continue Reading
Pennsylvania Housing Finds Its October Holding Pattern

Updated Category News Views 108

Pennsylvania's October housing numbers have the uneasy stillness of a pond before somebody throws a rock. The statewide median sales price sat at $315,000, exactly where it was in September, while sales barely cleared 10,400 and available listings kept inching higher. Nothing in that mix screams boom or bust. Frankly, that is the point: a market can look calm on the...

Continue Reading
San Bernardino Teamsters Back Their Historic Contract

Updated Category News Views 94

A 90% vote does not whisper; it rattles the filing cabinets. More than 12,000 San Bernardino County members of Teamsters Local 1932 have ratified a new labor agreement with over 90% approval, according to the union’s November 20 announcement. In a public-sector negotiation, that kind of margin matters because it tells management the workforce is not merely accepting a...

Continue Reading
Oatly’s $4.13 Tender Offer Is a Legal Detour, Not a Sale

Updated Category News Views 100

A $4.13 cash offer trading against a $7.17 close is the sort of thing that makes investors squint hard, and Verlinvest is practically waving a flag telling them why. This is not a conventional attempt to buy Oatly Group AB. It is a technical tender offer built to satisfy Swedish takeover rules while Verlinvest buys out its joint-venture partner’s interest in Oatly’s...

Continue Reading
CVRx Lawsuit Puts a Hard Date on Investor Decisions

Updated Category News Views 65

One ugly filing after the bell can vaporize years of shareholder confidence, and CVRx just supplied the painful exhibit. On August 7, 2026, shares of CVRx fell $3.55, or 59.76%, to close at $2.39 after the company disclosed a U.S. Department of Justice civil investigative demand in its August 6 Form 10-Q. That is not a routine bad quarter. It is the sort of disclosure...

Continue Reading
Digital Diabetes Care Has a Bigger Prize Than Devices

Updated Category News Views 144

A glucose sensor is becoming less a gadget than a running conversation between patient, clinician and software. That shift matters because diabetes management is leaving the occasional clinic visit and moving into daily life, where the useful product is not merely a reading but a pattern someone can act on. The sector deserves attention from investors, but it also...

Continue Reading
Veterinary Biologics Growth Has a Valuable Catch Ahead

Updated Category News Views 124

Pet allergies and livestock disease are hardly glamorous, yet they are becoming a durable spending lane. The veterinary biologics market is projected to rise from $2.85 billion in 2026 to $3.69 billion by 2031, a 5.3% compound annual growth rate. That is not the kind of growth figure that makes anyone pound the table, and frankly it should not. It is the sort that can...

Continue Reading
APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
GIGABYTE Pitches Local AI Agents to Enterprise Buyers

Updated Category News Views 72

Enterprise AI has reached the awkward stage where a slick chatbot demo no longer cuts it. GIGABYTE used its November 13 AI Partner Summit at the Pacific Palms Resort to make a more grounded pitch: companies need hardware and software setups that can put AI agents to work without casually tossing proprietary information into somebody else’s cloud. That is a sensible...

Continue Reading
Re-Decking or Rebuilding Starts Below the Deck Boards

Updated Category News Views 47

A weathered deck can fool the eye in both directions: ugly boards may sit atop solid framing, while a tidy surface can hide trouble where nobody bothers to look. That is the useful, sober point in Dawn Walsh's guidance for Knoxville homeowners. The decision is not really about whether the top boards look tired. It is about whether the bones underneath still deserve...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover Sustainability LIVE: The Middle East Summit 2026 Insights

Updated Category News Views 218

BizClik Announces Sustainability LIVE: The Middle East Summit BizClik, the renowned global B2B media company behind the well-known Sustainability Magazine, is setting the stage for an ambitious event called Sustainability LIVE: The Middle East Summit. This summit is scheduled to take place virtually from 3-4 February 2026, providing a unique opportunity for leaders in...

Continue Reading
Bureau Veritas Ceases Discussions on Business Merger Plans

Updated Category News Views 137

Bureau Veritas Concludes Discussions on Future Collaboration In a recent declaration, Bureau Veritas disclosed that discussions surrounding a potential merger with SGS have ceased. The talks, which commenced with optimism about the potential synergies between the two leading firms in the Testing, Inspection, and Certification (TIC) industry, did not reach a conclusive...

Continue Reading
Bernstein's Insights: Why Royal Caribbean Outshines Carnival

Updated Category News Views 295

Bernstein Analyzes the Cruise Industry Landscape Recently, Bernstein analysts took a deep dive into the cruise industry, comparing two major players: Royal Caribbean (NYSE: RCL) and Carnival (NYSE: CCL). The analysts have awarded an Outperform rating to Royal Caribbean while assigning a Market-Perform rating to Carnival, based on recent assessments of the sector....

Continue Reading
NRG Energy's Impressive Q4 Performance and Exciting Future Plans

Updated Category News Views 498

NRG Energy Reports Strong Fourth Quarter Performance NRG Energy, Inc. (NYSE: NRG) has witnessed an uptick in its stock price following the announcement of its fourth-quarter results for 2024. Despite missing revenue expectations, the company demonstrated remarkable profitability. Revenue and Earnings Overview During the fourth quarter, NRG Energy reported revenues of...

Continue Reading
OpenText Introduces Cutting-Edge AI Platform for Enterprises

Updated Category News Views 317

Transforming Data Management with AI Technology OpenText has unveiled an exciting new platform that revolutionizes how enterprises manage their data. This next-generation AI Data Platform streamlines data management while incorporating innovative AI capabilities that empower organizations to activate their information securely. As the digital landscape continues to...

Continue Reading